Barbara Mary Fingleton

List of Publications by Year in Descending Order

90 papers	10,428 citations	43 h-index	100 g-index
100 ext. papers	11,133 ext. citations	8.6 avg, IF	6.28 L-index

#	Paper	IF	Citations
90	Measurement of Metabolites from Migrating Cells. *Methods in Molecular Biology*, **2021**, 2294, 143-150	1.4	
89	Glycosylation as a regulator of site-specific metastasis.. *Cancer and Metastasis Reviews*, **2021**, 41, 107	9.6	1
88	Development of a novel murine model of lymphatic metastasis. *Clinical and Experimental Metastasis* , **2020**, 37, 247-255	4.7	3
87	Blood vessel epicardial substance (BVES) reduces LRP6 receptor and cytoplasmic -catenin levels to modulate Wnt signaling and intestinal homeostasis. *Carcinogenesis*, **2019**,	4.6	5
86	Non-canonical roles for metabolic enzymes and intermediates in malignant progression and metastasis. *Clinical and Experimental Metastasis*, **2019**, 36, 211-224	4.7	5
85	The importance of developing therapies targeting the biological spectrum of metastatic disease. *Clinical and Experimental Metastasis*, **2019**, 36, 305-309	4.7	7
84	Matrix metalloproteinases as regulators of inflammatory processes. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2017**, 1864, 2036-2042	4.9	100
83	MMPs **2017**, 591-601		
82	Perspective on the interpretation of research and translation to clinical care with therapy-associated metastatic breast cancer progression as an example. *Clinical and Experimental Metastasis*, **2017**, 34, 443-447	4.7	
81	Stromal matrix metalloproteinase 2 regulates collagen expression and promotes the outgrowth of experimental metastases. *Journal of Pathology*, **2015**, 235, 773-83	9.4	36
80	Interleukin-5 facilitates lung metastasis by modulating the immune microenvironment. *Cancer Research*, **2015**, 75, 1624-1634	10.1	60
79	IL4 receptor □mediates enhanced glucose and glutamine metabolism to support breast cancer growth. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2015**, 1853, 1219-28	4.9	35
78	Moving targets: Emerging roles for MMPs in cancer progression and metastasis. *Matrix Biology*, **2015**, 44-46, 200-6	11.4	287
77	Targeting IL4/IL4R for the treatment of epithelial cancer metastasis. *Clinical and Experimental Metastasis*, **2015**, 32, 847-56	4.7	54
76	Selenoprotein P influences colitis-induced tumorigenesis by mediating stemness and oxidative damage. *Journal of Clinical Investigation*, **2015**, 125, 2646-60	15.9	62
75	IL4 receptor ILR4□regulates metastatic colonization by mammary tumors through multiple signaling pathways. *Cancer Research*, **2014**, 74, 4329-40	10.1	63
74	Macrophages promote progression of spasmolytic polypeptide-expressing metaplasia after acute loss of parietal cells. *Gastroenterology*, **2014**, 146, 1727-38.e8	13.3	71

73	Lessons from immunology: IL4R directly promotes mammary tumor metastasis. *OncoImmunology*, **2014**, 3, e955373	7.2	11
72	MMPs **2014**, 1-11		
71	Matrix Metallopeptidase-10/Stromelysin 2 **2013**, 774-778		1
70	Targeting the Wnt pathway in synovial sarcoma models. *Cancer Discovery*, **2013**, 3, 1286-301	24.4	56
69	Systems-level analysis of proteolytic events in increased vascular permeability and complement activation in skin inflammation. *Science Signaling*, **2013**, 6, rs2	8.8	89
68	Dietary selenium deficiency exacerbates DSS-induced epithelial injury and AOM/DSS-induced tumorigenesis. *PLoS ONE*, **2013**, 8, e67845	3.7	64
67	Proteases in Cancer: Significance for Invasion and Metastasis **2013**, 491-550		8
66	Cytokine stimulation of epithelial cancer cells: the similar and divergent functions of IL-4 and IL-13. *Cancer Research*, **2012**, 72, 6338-43	10.1	90
65	An osteoblast-derived proteinase controls tumor cell survival via TGF-beta activation in the bone microenvironment. *PLoS ONE*, **2012**, 7, e29862	3.7	30
64	Lack of MMP10 exacerbates experimental colitis and promotes development of inflammation-associated colonic dysplasia. *Laboratory Investigation*, **2012**, 92, 1749-59	5.9	51
63	Kaiso directs the transcriptional corepressor MTG16 to the Kaiso binding site in target promoters. *PLoS ONE*, **2012**, 7, e51205	3.7	15
62	MTGR1 is required for tumorigenesis in the murine AOM/DSS colitis-associated carcinoma model. *Cancer Research*, **2011**, 71, 1302-12	10.1	31
61	Phase II AIDS Malignancy Consortium trial of topical halofuginone in AIDS-related Kaposi sarcoma. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2011**, 56, 64-8	3.1	40
60	Cleavage of E-Cadherin by Matrix Metalloproteinase-7 Promotes Cellular Proliferation in Nontransformed Cell Lines via Activation of RhoA. *Journal of Oncology*, **2010**, 2010, 530745	4.5	36
59	Matrix metalloproteinase-7 and premalignant host responses in Helicobacter pylori-infected mice. *Cancer Research*, **2010**, 70, 30-5	10.1	16
58	Epithelial interleukin-4 receptor expression promotes colon tumor growth. *Carcinogenesis*, **2010**, 31, 1010-7	4.6	79
57	Host-derived interleukin-5 promotes adenocarcinoma-induced malignant pleural effusion. *American Journal of Respiratory and Critical Care Medicine*, **2010**, 182, 1273-81	10.2	47
56	A new dress code for MMPs: cleavage optional. *Developmental Cell*, **2010**, 18, 3-4	10.2	2

55	Cancer in Context: Importance of the Tumor Microenvironment **2010**, 43-63		
54	Matrix metalloproteinase-9 contributes to intestinal tumourigenesis in the adenomatous polyposis coli multiple intestinal neoplasia mouse. *International Journal of Experimental Pathology*, **2008**, 89, 466-75	2.8	33
53	MMPs as therapeutic targets--still a viable option?. *Seminars in Cell and Developmental Biology*, **2008**, 19, 61-8	7.5	216
52	Effect of ablation or inhibition of stromal matrix metalloproteinase-9 on lung metastasis in a breast cancer model is dependent on genetic background. *Cancer Research*, **2008**, 68, 6251-9	10.1	108
51	A protective role of mast cells in intestinal tumorigenesis. *Carcinogenesis*, **2008**, 29, 880-6	4.6	75
50	Host nuclear factor-kappaB activation potentiates lung cancer metastasis. *Molecular Cancer Research*, **2008**, 6, 364-71	6.6	51
49	Use of bioluminescent imaging to investigate the role of nuclear factor-kappaBeta in experimental non-small cell lung cancer metastasis. *Clinical and Experimental Metastasis*, **2008**, 25, 43-51	4.7	12
48	Establishment and quantitative imaging of a 3D lung organotypic model of mammary tumor outgrowth. *Clinical and Experimental Metastasis*, **2008**, 25, 877-85	4.7	15
47	Functional colonography of Min mice using dark lumen dynamic contrast-enhanced MRI. *Magnetic Resonance in Medicine*, **2008**, 60, 718-26	4.4	9
46	MMP Inhibitor Clinical Trials The Past, Present, and Future **2008**, 759-785		9
45	Noninvasive Detection of Matrix Metalloproteinase Activity In Vivo using a Novel Magnetic Resonance Imaging Contrast Agent with a Solubility Switch. *Molecular Imaging*, **2007**, 6, 7290.2007.00035	3.7	49
44	Epithelial NF-kappaB activation promotes urethane-induced lung carcinogenesis. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 18514-9	11.5	156
43	Matrix metalloproteinases as valid clinical targets. *Current Pharmaceutical Design*, **2007**, 13, 333-46	3.3	220
42	A rat monoclonal antibody that recognizes pro- and active MMP-7 indicates polarized expression in vivo. *Hybridoma*, **2007**, 26, 22-7		19
41	Matrix metalloproteinase 7 mediates mammary epithelial cell tumorigenesis through the ErbB4 receptor. *Cancer Research*, **2007**, 67, 6760-7	10.1	54
40	Loss of functional Fas ligand enhances intestinal tumorigenesis in the Min mouse model. *Cancer Research*, **2007**, 67, 4800-6	10.1	18
39	Hu/Mu ProtIn oligonucleotide microarray: dual-species array for profiling protease and protease inhibitor gene expression in tumors and their microenvironment. *Molecular Cancer Research*, **2007**, 5, 443-54	6.6	16
38	Resident stromal cell-derived MMP-9 promotes the growth of colorectal metastases in the liver microenvironment. *International Journal of Cancer*, **2007**, 121, 495-500	7.5	43

37	Molecular targets in metastasis: lessons from genomic approaches. *Cancer Genomics and Proteomics*, **2007**, 4, 211-21	3.3	17
36	Noninvasive detection of matrix metalloproteinase activity in vivo using a novel magnetic resonance imaging contrast agent with a solubility switch. *Molecular Imaging*, **2007**, 6, 393-403	3.7	30
35	Matrix metalloproteinase-9 from bone marrow-derived cells contributes to survival but not growth of tumor cells in the lung microenvironment. *Cancer Research*, **2006**, 66, 259-66	10.1	142
34	Analysis of host- and tumor-derived proteinases using a custom dual species microarray reveals a protective role for stromal matrix metalloproteinase-12 in non-small cell lung cancer. *Cancer Research*, **2006**, 66, 7968-75	10.1	72
33	Matrix metalloproteinases: roles in cancer and metastasis. *Frontiers in Bioscience - Landmark*, **2006**, 11, 479-91	2.8	231
32	Proliferative effects of apical, but not basal, matrix metalloproteinase-7 activity in polarized MDCK cells. *Experimental Cell Research*, **2005**, 303, 308-20	4.2	26
31	Host□tumor interactions influencing cancer progression. *Drug Discovery Today Disease Mechanisms*, **2005**, 2, 199-204		
30	MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. *Cancer Cell*, **2005**, 7, 485-96	24.3	312
29	Increased plasma MMP9 in integrin alpha1-null mice enhances lung metastasis of colon carcinoma cells. *International Journal of Cancer*, **2005**, 116, 52-61	7.5	54
28	An orthotopic model of lung cancer to analyze primary and metastatic NSCLC growth in integrin alpha1-null mice. *Clinical and Experimental Metastasis*, **2005**, 22, 185-93	4.7	22
27	Proteinase activity in human and murine saliva as a biomarker for proteinase inhibitor efficacy. *Clinical Cancer Research*, **2004**, 10, 7865-74	12.9	22
26	Abnormal TNF activity in Timp3-/- mice leads to chronic hepatic inflammation and failure of liver regeneration. *Nature Genetics*, **2004**, 36, 969-77	36.3	251
25	Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. *Cancer Cell*, **2004**, 6, 409-21	24.3	940
24	Tcf binding sequence and position determines beta-catenin and Lef-1 responsiveness of MMP-7 promoters. *Molecular Carcinogenesis*, **2004**, 41, 125-39	5	46
23	Development of a novel fluorogenic proteolytic beacon for in vivo detection and imaging of tumour-associated matrix metalloproteinase-7 activity. *Biochemical Journal*, **2004**, 377, 617-28	3.8	153
22	Apoptotic responses common to cancer and inflammation **2004**, 123-145		
21	The influence of matrix metalloproteinase-7 on early mammary tumorigenesis in the multiple intestinal neoplasia mouse. *Oncology Reports*, **2004**, 12, 13-7	3.5	21
20	Matrix metalloproteinase inhibitors for cancer therapy:the current situation and future prospects. *Expert Opinion on Therapeutic Targets*, **2003**, 7, 385-97	6.4	98

19	CMT-3. CollaGenex. *Current Opinion in Investigational Drugs*, **2003**, 4, 1460-7		9
18	Identification of novel matrix metalloproteinase-7 (matrilysin) cleavage sites in murine and human Fas ligand. *Archives of Biochemistry and Biophysics*, **2002**, 408, 155-61	4.1	127
17	Matrix metalloproteinase inhibitors and cancer: trials and tribulations. *Science*, **2002**, 295, 2387-92	33.3	2274
16	Matrilysin (matrix metalloproteinase-7) selects for apoptosis-resistant mammary cells in vivo. *Cancer Research*, **2002**, 62, 5559-63	10.1	44
15	Matrix metalloproteinases as targets for therapy in Kaposi sarcoma. *Current Opinion in Oncology*, **2001**, 13, 368-73	4.2	14
14	From tadpoles to TIMPs making the most of MMPs. *Trends in Cell Biology*, **2001**, 11, 456-457	18.3	
13	From tadpoles to TIMPs making the most of MMPs. *Trends in Cell Biology*, **2001**, 11, 456-457	18.3	
12	The PEA3 subfamily of Ets transcription factors synergizes with beta-catenin-LEF-1 to activate matrilysin transcription in intestinal tumors. *Molecular and Cellular Biology*, **2001**, 21, 1370-83	4.8	155
11	Matrilysin [MMP-7] expression selects for cells with reduced sensitivity to apoptosis. *Neoplasia*, **2001**, 3, 459-68	6.4	125
10	Matrix metalloproteinases: biologic activity and clinical implications. *Journal of Clinical Oncology*, **2000**, 18, 1135-49	2.2	1276
9	Matrix metalloproteinase-3-dependent generation of a macrophage chemoattractant in a model of herniated disc resorption. *Journal of Clinical Investigation*, **2000**, 105, 133-41	15.9	142
8	Matrix metalloproteinase-7-dependent release of tumor necrosis factor-alpha in a model of herniated disc resorption. *Journal of Clinical Investigation*, **2000**, 105, 143-50	15.9	281
7	The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors. *Oncogene*, **1999**, 18, 2883-91	9.2	598
6	The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis. *Current Biology*, **1999**, 9, 1441-7	6.3	362
5	Cytokine regulation of matrilysin gene expression. *Biochemical Society Transactions*, **1997**, 25, 155S	5.1	1
4	Role of matrix metalloproteinases in invasion and metastasis: biology, diagnosis and inhibitors **1994**, 367-384		
3	Role of matrix metalloproteinases in invasion and metastasis: biology, diagnosis and inhibitors. *Cytotechnology*, **1993**, 12, 367-84	2.2	16
2	Role of Matrix Metalloproteinases in Tumor Invasion and Metastasis183-190		

1	The influence of matrix metalloproteinase-7 on early mammary tumorigenesis in the multiple intestinal neoplasia mouse. *Oncology Reports*,	3·5	3